University Teaching Hospital Markusovszky
- Address
- lock Available on a paid plan
University Teaching Hospital Markusovszky - Multispecialty Clinical Research Center
University Teaching Hospital Markusovszky is a comprehensive academic medical center conducting advanced clinical research across multiple therapeutic areas. The institution demonstrates particular expertise in cardiovascular medicine, dermatological conditions, respiratory diseases, and oncology, participating in pivotal international trials evaluating novel therapeutic approaches for serious medical conditions.
- Cardiovascular Research: Investigation of anticoagulant therapies for stroke prevention in atrial fibrillation and post-acute coronary syndrome management
- Dermatology and Immunology: Clinical evaluation of innovative treatments for moderate-to-severe atopic dermatitis using biologics and small molecule therapies
- Respiratory Medicine: Long-term safety studies of biologic agents for moderate-to-severe asthma
- Hematologic Oncology: Novel immunotherapy combinations for diffuse large B-cell lymphoma (DLBCL)
The research center's participation in phase II and III trials reflects its commitment to advancing evidence-based medicine and bringing cutting-edge treatments to patients. The facility's involvement in studies evaluating factor XIa inhibitors, targeted immunotherapies, and monoclonal antibodies demonstrates its capability to conduct complex, multi-arm comparative effectiveness trials that shape future treatment paradigms across diverse medical specialties.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 95 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 90 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Teaching Hospital Markusovszky
lock Showing 1 of 53 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 95 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 4 | Unknown | 2022-10-28 | 2024-07-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.